Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin's Lymphoma: An Open-Label Phase 1 Trial

The Lancet - United Kingdom
doi 10.1016/s0140-6736(15)00590-5
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial

The Lancet Oncology
Oncology
2011English

Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)

BMJ Open
Medicine
2020English

Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Cd30-Chimeric Antigen Receptor (Car) T Cells for Therapy of Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Irinotecan–temozolomide With Temsirolimus or Dinutuximab in Children With Refractory or Relapsed Neuroblastoma (COG ANBL1221): An Open-Label, Randomised, Phase 2 Trial

The Lancet Oncology
Oncology
2017English

768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy